Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decline in revenues for fiscal 2023. The company’s full-year net loss widened from the prior year. Revenues decreased 19% from last year to $8.27 million in fiscal 2023. A 17% increase in service revenues was more than offset by a sharp fall […]
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decline in revenues for fiscal 2023. The company’s full-year net loss widened from the prior year. Revenues decreased 19% from last year to $8.27 million in fiscal 2023. A 17% increase in service revenues was more than offset by a sharp fall […]
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decline in revenues for fiscal 2023. The company’s full-year net loss widened from the prior year.
Revenues decreased 19% from last year to $8.27 million in fiscal 2023. A 17% increase in service revenues was more than offset by a sharp fall in product revenues.
As a result, the net loss attributable to Trxade Health widened to $17.84 million in FY23 from $3.47 million in the twelve months ended December 2022.
